The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Rusfertide reduces cytoreductive therapy requirements in polycythemia vera
Francesca Palandri, MD, PhD, University of Bologna, Bologna, Italy, discusses a sub-analysis of the Phase III VERIFY study (NCT05210790) evaluating rusfertide in patients with phlebotomy-dependent polycythemia vera (PV). She explains how rusfertide reduced the need for higher doses of cytoreductive therapy while helping patients maintain hematocrit control, highlighting its potential role in the future management of PV. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
